Which has better earnings & valuation, GLAS or GPCR?

Glass House Brands has higher revenue and earnings than Structure Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.98M 2.24 -$29.66M N/A N/A Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A

Which has stronger earnings and valuation, XERS or GLAS?

Xeris Biopharma has higher revenue and earnings than Glass House Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Xeris Biopharma $335.41M 5.70 $550K -$0.11 N/A Glass House Brands $176.98M 2.24 -$29.66M N/A N/A

Which has higher valuation & earnings, TRVI or GLAS?

Glass House Brands has higher revenue and earnings than Trevi Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Glass House Brands $176.98M 2.24 -$29.66M N/A N/A

Which has preferable earnings & valuation, GLAS or ANIP?

ANI Pharmaceuticals has higher revenue and earnings than Glass House Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.98M 2.24 -$29.66M N/A N/A ANI Pharmaceuticals $883.37M 1.92 $78.34M $4.64 15.92

Which has better earnings & valuation, CMPS or GLAS?

Glass House Brands has higher revenue and earnings than Compass Pathways. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compass Pathways N/A N/A -$287.86M -$4.62 N/A Glass House Brands $176.98M 2.24 -$29.66M N/A N/A

Glass House Brands (GLAS) Competitors

$3.96 -0.30 (-6.92%)

As of 10:06 AM Eastern

Compare

GLAS vs. GPCR, XERS, TRVI, ANIP, and CMPS

Should you buy Glass House Brands stock or one of its competitors? Glass House Brands's main competitors and comparable companies include Structure Therapeutics (GPCR), Xeris Biopharma (XERS), Trevi Therapeutics (TRVI), ANI Pharmaceuticals (ANIP), and Compass Pathways (CMPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Glass House Brands compare to Structure Therapeutics?

Glass House Brands (NYSE:GLAS) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

In the previous week, Structure Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 2 mentions for Structure Therapeutics and 1 mentions for Glass House Brands. Structure Therapeutics' average media sentiment score of 0.37 beat Glass House Brands' score of -1.00 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Glass House Brands	Negative
Structure Therapeutics	Neutral

Glass House Brands has higher revenue and earnings than Structure Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.98M	2.24	-$29.66M	N/A	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A

Structure Therapeutics has a net margin of 0.00% compared to Glass House Brands' net margin of -31.68%. Structure Therapeutics' return on equity of -25.56% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	-31.68%	-60.92%	-15.69%
Structure Therapeutics	N/A	-25.56%	-24.31%

91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Glass House Brands presently has a consensus target price of $16.00, suggesting a potential upside of 274.80%. Structure Therapeutics has a consensus target price of $110.91, suggesting a potential upside of 334.26%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Structure Therapeutics beats Glass House Brands on 10 of the 14 factors compared between the two stocks.

How does Glass House Brands compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Xeris Biopharma presently has a consensus target price of $13.20, suggesting a potential upside of 25.95%. Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 274.80%. Given Glass House Brands' higher possible upside, analysts plainly believe Glass House Brands is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Xeris Biopharma had 4 more articles in the media than Glass House Brands. MarketBeat recorded 5 mentions for Xeris Biopharma and 1 mentions for Glass House Brands. Xeris Biopharma's average media sentiment score of 0.68 beat Glass House Brands' score of -1.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Xeris Biopharma	Positive
Glass House Brands	Negative

Xeris Biopharma has a net margin of -5.12% compared to Glass House Brands' net margin of -31.68%. Xeris Biopharma's return on equity of 338.21% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Glass House Brands	-31.68%	-60.92%	-15.69%

Xeris Biopharma has higher revenue and earnings than Glass House Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41M	5.70	$550K	-$0.11	N/A
Glass House Brands	$176.98M	2.24	-$29.66M	N/A	N/A

Summary

Xeris Biopharma beats Glass House Brands on 12 of the 14 factors compared between the two stocks.

How does Glass House Brands compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

95.8% of Trevi Therapeutics shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Glass House Brands' net margin of -31.68%. Trevi Therapeutics' return on equity of -23.59% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Glass House Brands	-31.68%	-60.92%	-15.69%

Trevi Therapeutics presently has a consensus target price of $27.08, suggesting a potential upside of 105.33%. Glass House Brands has a consensus target price of $16.00, suggesting a potential upside of 274.80%. Given Glass House Brands' higher probable upside, analysts clearly believe Glass House Brands is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Glass House Brands has higher revenue and earnings than Trevi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Glass House Brands	$176.98M	2.24	-$29.66M	N/A	N/A

In the previous week, Trevi Therapeutics had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Trevi Therapeutics and 1 mentions for Glass House Brands. Trevi Therapeutics' average media sentiment score of 1.26 beat Glass House Brands' score of -1.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Positive
Glass House Brands	Negative

Summary

Trevi Therapeutics beats Glass House Brands on 9 of the 14 factors compared between the two stocks.

How does Glass House Brands compare to ANI Pharmaceuticals?

Glass House Brands (NYSE:GLAS) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Glass House Brands currently has a consensus target price of $16.00, suggesting a potential upside of 274.80%. ANI Pharmaceuticals has a consensus target price of $99.60, suggesting a potential upside of 34.79%. Given Glass House Brands' higher possible upside, analysts clearly believe Glass House Brands is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

ANI Pharmaceuticals has a net margin of 11.07% compared to Glass House Brands' net margin of -31.68%. ANI Pharmaceuticals' return on equity of 27.37% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	-31.68%	-60.92%	-15.69%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ANI Pharmaceuticals has higher revenue and earnings than Glass House Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.98M	2.24	-$29.66M	N/A	N/A
ANI Pharmaceuticals	$883.37M	1.92	$78.34M	$4.64	15.92

In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Glass House Brands. MarketBeat recorded 6 mentions for ANI Pharmaceuticals and 1 mentions for Glass House Brands. ANI Pharmaceuticals' average media sentiment score of 0.81 beat Glass House Brands' score of -1.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Glass House Brands	Negative
ANI Pharmaceuticals	Positive

Summary

ANI Pharmaceuticals beats Glass House Brands on 12 of the 14 factors compared between the two stocks.

How does Glass House Brands compare to Compass Pathways?

Compass Pathways (NASDAQ:CMPS) and Glass House Brands (NYSE:GLAS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

Compass Pathways has a net margin of 0.00% compared to Glass House Brands' net margin of -31.68%. Compass Pathways' return on equity of -49.63% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Glass House Brands	-31.68%	-60.92%	-15.69%

Glass House Brands has higher revenue and earnings than Compass Pathways.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Glass House Brands	$176.98M	2.24	-$29.66M	N/A	N/A

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Compass Pathways presently has a consensus target price of $23.36, indicating a potential upside of 94.64%. Glass House Brands has a consensus target price of $16.00, indicating a potential upside of 274.80%. Given Glass House Brands' higher possible upside, analysts clearly believe Glass House Brands is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Compass Pathways had 2 more articles in the media than Glass House Brands. MarketBeat recorded 3 mentions for Compass Pathways and 1 mentions for Glass House Brands. Compass Pathways' average media sentiment score of 0.97 beat Glass House Brands' score of -1.00 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Overall Sentiment
Compass Pathways	Positive
Glass House Brands	Negative

Summary

Compass Pathways beats Glass House Brands on 11 of the 14 factors compared between the two stocks.

Get Glass House Brands News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLAS vs. The Competition

Export

Metric	Glass House Brands	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$395.96M	$12.39B	$7.25B	$23.07B
Dividend Yield	N/A	2.64%	2.53%	3.72%
P/E Ratio	-5.62	800.14	275.60	28.61
Price / Sales	2.24	831.75	583.42	21.11
Price / Cash	N/A	15.28	27.30	19.30
Price / Book	N/A	9.13	10.83	4.72
Net Income	-$29.66M	$2.84B	$3.50B	$1.07B
7 Day Performance	-19.53%	-0.89%	-1.25%	0.03%
1 Month Performance	-45.90%	-3.67%	-4.02%	-3.39%
1 Year Performance	N/A	-3.95%	7.14%	9.40%

Glass House Brands Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLAS Glass House Brands	2.0317 of 5 stars	$3.97 -6.9%	$16.00 +303.5%	N/A	$372.96M	$176.98M	N/A	357	Negative News Short Interest Increase
GPCR Structure Therapeutics	2.2576 of 5 stars	$26.27 -1.5%	$110.91 +322.1%	-15.1%	$1.84B	N/A	N/A	281
XERS Xeris Biopharma	4.3947 of 5 stars	$10.03 -0.8%	$13.20 +31.6%	+31.2%	$1.83B	$291.85M	N/A	435	Gap Down
TRVI Trevi Therapeutics	2.9855 of 5 stars	$12.79 -2.7%	$27.08 +111.8%	+32.0%	$1.83B	N/A	N/A	34	Positive News
ANIP ANI Pharmaceuticals	4.0319 of 5 stars	$72.28 +0.5%	$98.00 +35.6%	-17.7%	$1.64B	$883.37M	15.41	970

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GLAS) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Glass House Brands (GLAS) Competitors

GLAS vs. GPCR, XERS, TRVI, ANIP, and CMPS

How does Glass House Brands compare to Structure Therapeutics?

Summary

How does Glass House Brands compare to Xeris Biopharma?

Summary

How does Glass House Brands compare to Trevi Therapeutics?

Summary

How does Glass House Brands compare to ANI Pharmaceuticals?

Summary

How does Glass House Brands compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Glass House Brands (GLAS) Competitors

GLAS vs. GPCR, XERS, TRVI, ANIP, and CMPS

How does Glass House Brands compare to Structure Therapeutics?

Does the media refer more to GLAS or GPCR?

Which has better earnings & valuation, GLAS or GPCR?

Is GLAS or GPCR more profitable?

Do institutionals and insiders have more ownership in GLAS or GPCR?

Do analysts prefer GLAS or GPCR?

Summary

How does Glass House Brands compare to Xeris Biopharma?

Do analysts prefer XERS or GLAS?

Do insiders and institutionals hold more shares of XERS or GLAS?

Does the media prefer XERS or GLAS?

Is XERS or GLAS more profitable?

Which has stronger earnings and valuation, XERS or GLAS?

Summary

How does Glass House Brands compare to Trevi Therapeutics?

Do institutionals & insiders have more ownership in TRVI or GLAS?

Is TRVI or GLAS more profitable?

Do analysts rate TRVI or GLAS?

Which has higher valuation & earnings, TRVI or GLAS?

Does the media prefer TRVI or GLAS?

Summary

How does Glass House Brands compare to ANI Pharmaceuticals?

Do analysts prefer GLAS or ANIP?

Is GLAS or ANIP more profitable?

Do insiders and institutionals hold more shares of GLAS or ANIP?

Which has preferable earnings & valuation, GLAS or ANIP?

Does the media refer more to GLAS or ANIP?

Summary

How does Glass House Brands compare to Compass Pathways?

Is CMPS or GLAS more profitable?

Which has better earnings & valuation, CMPS or GLAS?

Do insiders and institutionals believe in CMPS or GLAS?

Do analysts rate CMPS or GLAS?

Does the media favor CMPS or GLAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLAS vs. The Competition

Glass House Brands Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools